Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients.
Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients.
复制标题
DOI：
10.1155/2014/269613
复制
发表时间：
2014
影响因子：
2.5
通讯作者：
Shigematsu T
中科院分区：
文献类型：
--
作者：
Okamoto M;Yamanaka S;Yoshimoto W;Shigematsu T
肾移植受者发生继发性骨质疏松症诱导的免疫抑制药物，骨折的风险很高，腹主动脉钙化（AC）是一个已知的心血管死亡率的预测因子。在这项对12名稳定的肾移植受者的研究中，我们评估了双膦酸盐治疗对骨丢失和AC进展的预防作用。我们将受试者随机分为阿仑膦酸钠治疗组（A组：5例受试者）和对照组（C组：7例受试者）。A组患者在24个月内接受35 mg/周的阿仑膦酸钠治疗，而C组患者不接受任何双膦酸盐治疗。确定了两个主要终点：（1）使用DEXA估计的骨矿物质密度（BMD）的时间依赖性变化和（2）腹部AC的进展，使用计算机断层扫描数据计算两次作为指数（ACI）。在2年的研究期间，A组患者的BMD显著增加1.86 ± 0.85%（与基线相比P = 0.015），几乎完全抑制ACI进展（38.2 ± 24.2%至39.6 ± 24.3%），而C组随着ACI进展和骨丢失，BMD下降幅度逐渐减小（32.8 ± 25.0%~ 37.8 ± 29.2%，P = 0.061）。总之，阿仑膦酸钠治疗是一种有效的治疗继发性骨质疏松症和血管钙化的肾移植受者异位钙化。本临床试验在JMACCT CTR注册，注册号为JMA-IIA 00155。
Kidney transplant recipients develop secondary osteoporosis induced by immunosuppressive medication, with a high risk of fracture, and abdominal aortic calcification (AC) is a known predictor of cardiovascular mortality. In this study of 12 stable kidney recipients, we estimated the preventive effect of bisphosphonate treatment on bone loss and progression of AC. We randomly divided the subjects into a treatment group with alendronate (group A: 5 subjects) and a control group (group C: 7 subjects). Group A patients received 35 mg/week of alendronate over 24 months, while group C patients were not administered with any bisphosphonates. Two major endpoints were established: (1) the time-dependent change in bone mineral density (BMD) estimated with DEXA and (2) progression of abdominal AC, calculated twice as an index (ACI) using computed tomography data. Over the 2-year study period, group A patients showed significantly increased BMD of 1.86 ± 0.85% (P = 0.015 versus baseline), and almost complete inhibition of ACI progression (38.2 ± 24.2% to 39.6 ± 24.3%), but group C patients showed a decrease in BMD decline with bone loss and progression of ACI (32.8 ± 25.0% to 37.8 ± 29.2%, P = 0.061). In conclusion, alendronate therapy was an effective treatment in kidney transplant recipients for secondary osteoporosis and vascular calcification as ectopic calcification. This clinical trial is registered with number JMA-IIA00155 of JMACCT CTR.
登录
查看更多内容
影响因子：
19.6
作者：
Lomashvili, Koba A.;Monier-Faugere, Marie-Claude;Wang, Xiaonan;Malluche, Hartmut H.;O'Neill, W. Charles
通讯作者：
O'Neill, W. Charles
影响因子：
3.2
作者：
Kalantar-Zadeh K;Molnar MZ;Kovesdy CP;Mucsi I;Bunnapradist S
通讯作者：
Bunnapradist S
影响因子：
24
作者：
Elmariah, Sammy;Delaney, Joseph A. C.;O'Brien, Kevin D.;Budoff, Matthew J.;Vogel-Claussen, Jens;Fuster, Valentin;Kronmal, Richard A.;Halperin, Jonathan L.
通讯作者：
Halperin, Jonathan L.
影响因子：
158.5
作者：
LIBERMAN, UA;WEISS, SR;KARPF, DB
通讯作者：
KARPF, DB
DOI：
10.1097/01.asn.0000087092.53894.80
发表时间：
2003-10-01
影响因子：
13.6
作者：
Coco, M;Glicklich, D;Malluche, H
通讯作者：
Malluche, H